Clinical Trials

Anatomic Stage III Breast Cancer AJCC v8

NCT07340541 2026-04-13

EVOLVE-BDT

700 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02523014 2026-04-07

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

124 enrolled

CNS

Meningioma

NCT07112053 2026-04-06

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

40 enrolled

Anatomic Stage IV Breast Cancer AJCC v8

NCT02693535 2026-04-02

TAPUR

4,200 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT06365788 2026-04-01

ABBICAR

53 enrolled

Bulbo-Spinal Atrophy, X-Linked, Triple Negative Breast Neoplasms

NCT05999994 2026-03-27

CAMPFIRE

105 enrolled

Neoplasms

NCT07209449 2026-03-18

A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer

75 enrolled

Recurrence, Endometrial Neoplasms

NCT01042379 2026-03-13

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT05940493 2026-03-13

Abemaciclib in Newly Diagnosed Meningioma Patients

72 enrolled

CNS

Meningioma

NCT05524584 2026-03-11

Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer

20 enrolled

Breast Neoplasms

NCT05708235 2026-03-05

MiRaDoR

976 enrolled

Breast Neoplasms, Neoplasm, Residual

NCT06366347 2026-02-11

ALPINE: Maintenance Letrozole/Abemaciclib

32 enrolled

Endometrial Neoplasms

NCT05305924 2026-01-28

Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer

28 enrolled

ER-Positive Breast Cancer

NCT05933395 2026-01-20

GERTRUDE

135 enrolled

Neoplasm Metastasis

NCT05501704 2026-01-07

ETHAN - ET for Male BC

Breast Neoplasms, Male

NCT06409390 2025-12-04

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

15 enrolled

Breast Neoplasms

NCT02977780 2025-11-10

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

460 enrolled

CNS

Glioblastoma

NCT06062498 2025-10-20

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

174 enrolled

Breast Neoplasms

NCT04305834 2025-09-24

Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.

43 enrolled

Breast Neoplasms

NCT03310879 2025-09-02

Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6

38 enrolled

Neoplasms

NCT04469764 2025-07-29

Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer

32 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT04040205 2025-07-20

Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration

Other solid neoplasmSarcoma

44 enrolled

Chondrosarcoma, Retinoblastoma, Sarcoma, Osteosarcoma

NCT03675893 2025-06-15

RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer

180 enrolled

Ovarian Neoplasms, Endometrial Neoplasms

NCT04614194 2025-06-02

Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib

Breast Neoplasms

NCT04523857 2025-04-04

ABBY

66 enrolled

Breast Neoplasms

NCT05872204 2025-03-19

ALEPRO

100 enrolled

Low Grade Serous Ovarian Carcinoma

NCT06259929 2025-02-18

Neo-AGILE

51 enrolled

Breast Neoplasms

NCT05159245 2024-07-15

FINPROVE

Other hematologic neoplasm

250 enrolled

Hematologic Neoplasms

NCT02925234 2024-01-24

DRUP

1,550 enrolled

Neoplasms

NCT05766410 2023-03-16

ORACLE-RIPA